Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07851779 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Withdrawal of Heart Failure Treatment Patients With Non-ischemic Cardiomyopathy Who Have Been Super-responders to Cardiac Resynchronization Therapy.

Study acronym: DRUGLESS-CRT
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Multicenter, prospective, non-inferiority, randomized, single-blind (primary endpoint evaluators blinded, patients not blinded) clinical trial. We aim to evaluate if the withdrawal of heart failure treatment is safe in patients with non-ischemic cardiomyopathy, negative genetic test, no evidence of late gadolinium enhancement on cardiac MRI, who have been super-responders to cardiac resynchronization therapy and remain free of heart failure events for at least 6 months after device implantation.
Trial Details
NCT Number NCT07851779
Lead Sponsor Institut d'Investigació Biomèdica de Bellvitge
Collaborators: University Hospital Virgen de las Nieves, Hospital de Sant Pau, Hospital Vall d'Hebron, Hospital Universitario La Paz, Hospital Universitari de Bellvitge
Conditions
(from sponsor)		 Non-ischemic Cardiomyopathy, Cardiac Resynchronisation Therapy (CRT)
Enrollment 64 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov